The GLP-1 analogue LIR has shown neuroprotective effects in a range of animal models of neurodegenerative disorders, such as AD (McClean et al. 2011; McClean and Holscher 2014; Hansen et al. 2015), Parkinson’s disease (Badawi et al. 2017; Liu et al. 2015), and status epilepticus (Wang et al. 2018). Here, GCG is linked to Parkinson disease.